(Q42994454)

English

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy

scientific article published in September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

2

object named as

Naoya Sakamoto

1 reference

Europe PubMed Central

12 November 2017

4

object named as

Namiki Izumi

1 reference

Europe PubMed Central

12 November 2017

author name string

Kosei Hamano

1

1 reference

Europe PubMed Central

12 November 2017

Nobuyuki Enomoto

3

1 reference

Europe PubMed Central

12 November 2017

Yasuhiro Asahina

5

1 reference

Europe PubMed Central

12 November 2017

Masayuki Kurosaki

6

1 reference

Europe PubMed Central

12 November 2017

Eri Ueda

7

1 reference

Europe PubMed Central

12 November 2017

Yoko Tanabe

8

1 reference

Europe PubMed Central

12 November 2017

Shinya Maekawa

9

1 reference

Europe PubMed Central

12 November 2017

Jun Itakura

10

1 reference

Europe PubMed Central

12 November 2017

Hideki Watanabe

11

1 reference

Europe PubMed Central

12 November 2017

Sei Kakinuma

12

1 reference

Europe PubMed Central

12 November 2017

Mamoru Watanabe

13

1 reference

Europe PubMed Central

12 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2005

1 reference

Europe PubMed Central

12 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

12 November 2017

20

1 reference

Europe PubMed Central

12 November 2017

9

1 reference

Europe PubMed Central

12 November 2017

1401-1409

1 reference

Europe PubMed Central

12 November 2017

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Course and outcome of hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Ribavirin causes error catastrophe during Hantaan virus replication.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Mechanisms of action of ribavirin in antiviral therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Therapy for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2005.04024.X

21 January 2018

Identifiers

10.1111/J.1440-1746.2005.04024.X

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42994454&oldid=1976273171"